CYP2C9 Genotype vs. Metabolic Phenotype for Individual Drug Dosing—A Correlation Analysis Using Flurbiprofen as Probe Drug

Vogl, Silvia; Lutz, Roman W.; Schönfelder, Gilbert; Lutz, Werner K.
March 2015
PLoS ONE;Mar2015, Vol. 10 Issue 3, p1
Academic Journal
Currently, genotyping of patients for polymorphic enzymes responsible for metabolic elimination is considered a possibility to adjust drug dose levels. For a patient to profit from this procedure, the interindividual differences in drug metabolism within one genotype should be smaller than those between different genotypes. We studied a large cohort of healthy young adults (283 subjects), correlating their CYP2C9 genotype to a simple phenotyping metric, using flurbiprofen as probe drug. Genotyping was conducted for CYP2C9*1, *2, *3. The urinary metabolic ratio MR (concentration of CYP2C9-dependent metabolite divided by concentration of flurbiprofen) determined two hours after flurbiprofen (8.75 mg) administration served as phenotyping metric. Linear statistical models correlating genotype and phenotype provided highly significant allele-specific MR estimates of 0.596 for the wild type allele CYP2C9*1, 0.405 for CYP2C9*2 (68 % of wild type), and 0.113 for CYP2C9*3 (19 % of wild type). If these estimates were used for flurbiprofen dose adjustment, taking 100 % for genotype *1/*1, an average reduction to 84 %, 60 %, 68 %, 43 %, and 19 % would result for genotype *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3, respectively. Due to the large individual variation within genotypes with coefficients of variation ≥ 20 % and supposing the normal distribution, one in three individuals would be out of the average optimum dose by more than 20 %, one in 20 would be 40 % off. Whether this problem also applies to other CYPs and other drugs has to be investigated case by case. Our data for the given example, however, puts the benefit of individual drug dosing to question, if it is exclusively based on genotype.


Related Articles

  • Validation of incorporating flurbiprofen into the Pittsburgh cocktail*. Zgheib, Nathalie K.; Frye, Reginald F.; Tracy, Timothy S.; Romkes, Marjorie; Branch, Robert A. // Clinical Pharmacology & Therapeutics;Sep2006, Vol. 80 Issue 3, p257 

    Background: We have previously shown that flurbiprofen metabolism to 4′-hydroxyflurbiprofen provides an in vivo measure of cytochrome P450 (CYP) 2C9 activity. This study evaluated the possibility of incorporating flurbiprofen into the current 5-drug Pittsburgh cocktail.Methods: In a...

  • Genetic Polymorphism of the Human Cytochrome P450 2C9 Gene and Its Clinical Significance. Bo Wang; Jing Wang; Shui-Qing Huang; Hai-Hao Su; Shu-Feng Zhou // Current Drug Metabolism;Sep2009, Vol. 10 Issue 7, p781 

    Human cytochrome P450 2C9 (CYP2C9) accounts for ~20% of total hepatic CYP content and metabolizes ~15% clinically used drugs including S-warfarin, tolbutamide, phenytoin, losartan, diclofenac, and celecoxib. To date, there are at least 33 variants of CYP2C9 (*1B through to *34) being identified....

  • Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2? Kesel, Pieter; Lambert, Willy; Stove, Christophe // Clinical Pharmacokinetics;Jul2015, Vol. 54 Issue 7, p771 

    Background and Objective: Although metabolite-to-parent drug concentration ratios in hair have been suggested as a possible tool to study the metabolism of drugs in a non-invasive way, no studies are available that evaluated this in a systematic way. Cytochrome P450 (CYP) 1A2 is a...

  • Distribution of CYP2D6 Alleles and Phenotypes in the Brazilian Population. Friedrich, Deise C.; Genro, Júlia P.; Sortica, Vinicius A.; Suarez-Kurtz, Guilherme; de Moraes, Maria Elizabete; Pena, Sergio D. J.; dos Santos, Ândrea K. Ribeiro; Romano-Silva, Marco A.; Hutz, Mara H. // PLoS ONE;Oct2014, Vol. 9 Issue 10, p1 

    Abstract: The CYP2D6 enzyme is one of the most important members of the cytochrome P450 superfamily. This enzyme metabolizes approximately 25% of currently prescribed medications. The CYP2D6 gene presents a high allele heterogeneity that determines great inter-individual variation. The aim of...

  • Age-Related Changes in Pharmacokinetics. Shi, Shaojun; Klotz, Ulrich // Current Drug Metabolism;Sep2011, Vol. 12 Issue 7, p601 

    Ageing is characterized by a progressive decline in the functional reserve of multiple organs and systems, which can influence drug disposition. In addition, comorbidity and polypharmacy are highly prevalent in the elderly. As ageing is associated with some reduction in first-pass metabolism,...

  • Changes in the defined daily dose; CYP2D6/CYP3A metabolism as an indicator for dose-setting problems. Stolk, P.; Heerdink, E.; Leufkens, H. // European Journal of Clinical Pharmacology;May2005, Vol. 61 Issue 3, p243 

    Objective: Interindividual variability is common at all stages of drug absorption, distribution, pharmacodynamics, metabolism and elimination. In this study, we focused on two enzymes involved in phase-I drug metabolism as markers of pharmacological variability: the CYP3A and CYP2D6 subsystems...

  • New Insights into the Structural Features and Functional Relevance of Human Cytochrome P450 2C9. Part I. Sui-Lin Mo; Zhi-Wei Zhou; Li-Ping Yang; Ming Qian Wei; Shu-Feng Zhou // Current Drug Metabolism;Dec2009, Vol. 10 Issue 10, p1075 

    CYP2C9 is one of the most abundant CYP enzymes in the human liver (∼20% of hepatic total CYP content). CYP2C9 metabolizes approximately 20% clinical drugs (>120 drugs), including a number of drugs with narrow therapeutic ranges. Some natural compounds are also metabolized, probably leading...

  • Prediction of Drug Metabolism: The Case of Cytochrome P450 2D6. N.P.E. Vermeulen // Current Topics in Medicinal Chemistry;Jul2003, Vol. 3 Issue 11, p1227 

    Cytochromes P450 (Cyt P450s) constitute the most important biotransformation enzymes involved in the biotransformation of drugs and other xenobiotics. Because drug metabolism by Cyt P450s plays such an important role in the disposition and in the pharmacological and toxicological effects of...

  • Drug-metabolizing cytochrome P450s in the brain. Miksys, Sharon L.; Tyndale, Rachel F. // Journal of Psychiatry & Neuroscience;Nov2002, Vol. 27 Issue 6, p406 

    Most CYP subfamilies have been identified in brain, but there is much more information available on the distribution and metabolic activity of CYP subfamilies in brain of rodents than in humans, and what we do know still lags far behind our knowledge of hepatic CYPs. With the constant...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics